Form 4 Dynatrace, Inc. For: May 15 Filed by: Greifeneder Bernd

Go back to Form 4 Dynatrace, Inc. For: May 15 Filed by: Greifeneder Bernd

Dynatrace Inc. (DT) PT Raised to $48 at Morgan Stanley

May 20, 2024 1:06 PM EDT

Morgan Stanley analyst Sanjit Singh raised the price target on Dynatrace Inc. (NYSE: DT) to $48.00 (from $40.00) while maintaining a Overweight rating.

The analyst comments "Updated DYNE-101 (DM1) and DYNE-251 (DMD) data, ahead of expectations (2H24, previously), indicate continued improvements at higher doses that importantly... More

JPMorgan Reiterates Overweight Rating on Dynatrace Inc. (DT)

May 20, 2024 12:31 PM EDT

JPMorgan analyst Sterling Auty reiterated an Overweight rating and $60.00 price target on Dynatrace Inc. (NYSE: DT).

The analyst comments "This morning, Dyne reported new data from the phase 1/2 ACHIEVE study for DYNE-101 in DM1 and the phase 1/2 DELIVER study for DYNE-251 in patients ages 6-14yo with DMD who are amenable to exon 51 skipping. Dyne expressed that... More

Dynatrace Inc. (DT) PT Lowered to $60 at FBN Securities

May 20, 2024 11:43 AM EDT

FBN Securities analyst Shebly Seyrafi lowered the price target on Dynatrace Inc. (NYSE: DT) to $60.00 (from $65.00) while maintaining a Outperform rating.

The analyst comments "We retain our Outperform rating on DT and lower our PT from $65 to $60 following its FQ3 report in which revenue grew by 21% Y/Y (and came in 1%... More